Fabio C Tucci

Fabio C Tucci is the current Chief Operating Officer at Epigen Biosciences. Prior to this, they were the Director of Chemistry at Tanabe Research Laboratories, USA from October 2006 to February 2010. There, they managed the “hit-to-lead” medicinal chemistry activities with the goal of transferring two advanced lead candidates/year into the pipeline of Mitsubishi-Tanabe Pharma Corporation (MTPC) in Japan. Fabio led a team of 13 chemists executing three medicinal chemistry projects in the hit-to-lead stage.

From October 1999 to September 2006, Tucci worked as a Principal Scientist at Neurocrine Biosciences where they developed ligands for the melanocortin subtype 4 receptor (MC4R): agonists for the treatment of obesity and antagonists for the treatment of cancer-cachexia. Fabio also worked on the early stages in the Medicinal Chemistry discovery of small molecule antagonists to the Gonadotropin-Releasing Hormone (GnRH) receptor for the treatment of endometriosis, BPH, prostate cancer and uterine fibroids. This series culminated with two clinical compounds (NBI 42902 and 56418-Elagolix). Elagolix is currently in Phase IIb for the treatment of endometriosis. Tucci supervised two Research Associates and two Scientists during their time at Neurocrine Biosciences.

Fabio C Tucci has a certificate in medicinal chemistry from the University of California San Diego Extension. Fabio also has post-doctoral degrees in supramolecular/organic chemistry from Scripps Research and organic chemistry from the University of Wisconsin-Madison. Their PhD is in organic chemistry from the Universidade de São Paulo, and they did an exchange program PhD in organic chemistry at the University of Michigan. Their BS is in chemistry from Pós Graduação - Faculdades Oswaldo Cruz, and they also attended Universidade Federal de Pernambuco.